Sarilumab
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Sarilumab (Sanofi/Regeneron) is a human monoclonal antibody interleukin (IL)-6 receptor antagonist in Phase III development for rheumatoid arthritis. IL-6 is a pro-inflammatory cytokine which plays an essential role in a wide variety of biological functions, including the final differentiation of B cells into immunoglobulin-secreting cells, as well as inducing myeloma/plasmacytoma growth and nerve cell differentiation.
Analyst Outlook
Sarilumab’s (Sanofi/Regeneron) clinical performance to date has been comparable to that of the first-to-market interleukin (IL)-6 inhibitor Actemra (tocilizumab; Chugai/Roche). Interviewed rheumatologists highlight that sarilumab’s lack of differentiation from its marketed competitor will prevent it from capturing significant share. Datamonitor Healthcare believes that unless sarilumab demonstrates superior efficacy in certain patient subgroups, and/or has a lower cost, its uptake in rheumatoid arthritis (RA) will be low as Actemra will remain rheumatologists’ IL-6 inhibitor of choice.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 sarilumab : Rheumatoid arthritis
LIST OF FIGURES
10 Figure 1: Sarilumab SWOT analysis in rheumatoid arthritis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of sarilumab
(Sanofi/Regeneron) for rheumatoid arthritis
12 Figure 3: Datamonitor Healthcare’s drug assessment scores and weightings of sarilumab
(Sanofi/Regeneron) for rheumatoid arthritis
LIST OF TABLES
4 Table 1: Sarilumab (Sanofi/Regeneron) drug profile
5 Table 2: Sarilumab’s pivotal Phase III trials in rheumatoid arthritis
7 Table 3: Results of the Phase III SARIL-RA-MOBILITY trial of sarilumab for rheumatoid arthritis
8 Table 4: Sarilumab: baseline and change by week 12 in quality of life scores for patients with
good EULAR responses
9 Table 5: Sarilumab: MOBILITY Part A efficacy results
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sirukumab 
Sign up to the